Perrigo Company plc
Perrigo provides over-the-counter health solutions globally. It operates through Consumer Self-Care segments for Americas and International markets. Products include upper respiratory, nutrition, digestive health, pain/sleep aids, oral care, and healthy lifestyle products. The company also offers skin care, womens health, vitamins/minerals, and rare diseases products. Its brands include Compeed, Dr. Fresh, Nasonex, and more. Products are sold through various channels, including retail stores, e-commerce, wholesalers, and pharmacies. The company was founded in 1887 and is headquartered in Dublin, Ireland.
Overview
Strengths
- Asset-light, cash-generative model: capital expenditure takes only 2.8% of revenue and free cash flow was positive in each of the last 6 years.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/FCF 14.9x vs. a median of 21.4x and EV/EBITDA 8.3x vs. a median of 12.9x.
- Cheaper than its own history: EV/EBITDA 8.3x vs. a historical average of 12.8x.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 3.6%) has been below its cost of capital of 5.2% in 5 of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- High leverage: net debt is 4.9x EBITDA, against a median of 1.4x for its Drug Manufacturers - Specialty & Generic peers.
Key Financial Data